Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (11-20 of 193) with videos related to

Pageof 20
Sort By:
Journal of the Peripheral Nervous System : JPNS|July 21, 2020
From pathogenesis to personalized treatments of neuropathies in hematological malignanciesChiara Briani, Andrea Visentin, Federica Cerri, et al.
Cancers|April 13, 2024
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative ReviewAndrea Visentin, Sara Frazzetto, Livio Trentin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 10, 2024
Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and managementYoung Gi Min, Andrea Visentin, Chiara Briani, et al.
Journal of Neurology|November 10, 2022
Vasculitic flare in a patient with anti-myelin-associated glycoprotein (MAG) antibody following mRNA-1273 SARS-CoV-2 vaccineChiara Briani, Sergio Ferrari, Matteo Tagliapietra, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2022
The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG AntibodiesChiara Briani, Andrea Visentin, Francesca Castellani, et al.
Diagnostics (Basel, Switzerland)|August 28, 2025
Explainable AI-Based Feature Selection Approaches for Raman SpectroscopyNicola Rossberg, Rekha Gautam, Katarzyna Komolibus, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 16, 2022
The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG AntibodiesChiara Briani, Andrea Visentin, Francesca Castellani, et al.
Medicina Clinica|December 23, 2023
Bleomycin-induced flagellate dermatitis in a patient with Hodgkin lymphomaNicolò Danesin, Alessandro Cellini, Francesco Piazza, et al.
Critical Reviews in Oncology/Hematology|November 23, 2025
Venetoclax and ibrutinib: Two partners for the front-line treatment of chronic lymphocytic leukemiaAndrea Visentin, Alessandro Cellini, Francesco Angotzi, et al.
ACS Omega|May 11, 2026
Automated Baseline Correction Evaluation Score for Raman SpectroscopySimone Innocente, Andrea Visentin, Stefan Andersson-Engels, et al.
Pageof 20

Showing results (11-20 of 193) with videos related to

Sort By:
Pageof 20
Journal of the Peripheral Nervous System : JPNS|July 21, 2020
From pathogenesis to personalized treatments of neuropathies in hematological malignanciesChiara Briani, Andrea Visentin, Federica Cerri, et al.
Cancers|April 13, 2024
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative ReviewAndrea Visentin, Sara Frazzetto, Livio Trentin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 10, 2024
Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and managementYoung Gi Min, Andrea Visentin, Chiara Briani, et al.
Journal of Neurology|November 10, 2022
Vasculitic flare in a patient with anti-myelin-associated glycoprotein (MAG) antibody following mRNA-1273 SARS-CoV-2 vaccineChiara Briani, Sergio Ferrari, Matteo Tagliapietra, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2022
The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG AntibodiesChiara Briani, Andrea Visentin, Francesca Castellani, et al.
Diagnostics (Basel, Switzerland)|August 28, 2025
Explainable AI-Based Feature Selection Approaches for Raman SpectroscopyNicola Rossberg, Rekha Gautam, Katarzyna Komolibus, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 16, 2022
The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG AntibodiesChiara Briani, Andrea Visentin, Francesca Castellani, et al.
Medicina Clinica|December 23, 2023
Bleomycin-induced flagellate dermatitis in a patient with Hodgkin lymphomaNicolò Danesin, Alessandro Cellini, Francesco Piazza, et al.
Critical Reviews in Oncology/Hematology|November 23, 2025
Venetoclax and ibrutinib: Two partners for the front-line treatment of chronic lymphocytic leukemiaAndrea Visentin, Alessandro Cellini, Francesco Angotzi, et al.
ACS Omega|May 11, 2026
Automated Baseline Correction Evaluation Score for Raman SpectroscopySimone Innocente, Andrea Visentin, Stefan Andersson-Engels, et al.
Pageof 20